Leishmaniasis country profile — 2015

Ethiopia



COUNTRY GENERAL INFORMATION (World Bank, 2015)

Total population:	99,873,033
Gender F /M (%):	50.1 / 49.9
Population, age group <15/≥15 years (%):	42 / 58
Life expectancy at birth (F/M, years) (2015):	67/ 63
GDP (PPP int \$):	1,500
Income status:	Low
Number of 1st sub-national administrative level divisions, name:	9, Region

EPIDEMIOLOGY	VL	

EPIDEMIOLOGY	VL	CLª	PKDL	MCL
Endemicity status:	Endemic	Endemic	Endemic	Endemic
Number of new cases (incidence):	2,063	No data	11	6
Number of relapse ¹ cases:	67	No data	0	0
Total number of cases:	2,141	528	11	0
Imported cases* (#, %):	73, 4%	No data	N/A	N/A
Gender distribution* (% F):	6	No data	No data	50
Age group distribution* (%, < 5/5-14/>14):	(2/10/88)	(2/20/78)	No data	(0/83/17)
Incidence rate (cases/10,000 population in endemic areas):	6.28	1.05	N/A	N/A
Number of endemic 1 st sub-national administrative level divisions:	6	3	N/A	N/A
Population at risk ² (%, $\#$ at risk/total population) ^b :	3 % 3,168,835, 99,878,03		N/A	N/A
Was there any outbreak?	No	No	N/A	N/A
Number of new ³ foci:	0	0	N/A	N/A


N/A = Not applicable; I Relapse in this country is defined for VL as: "A person with clinical features and a positive parasitology consistent with visceral leishmaniasis, after having been successfully treated for primary VL and discharged improved or with a negative test of cure. For CL: no definition available"; ² Defined as "Number of people living in 1st sub-national administrative level endemic areas"; ³ Defined as "In this reporting period, an area at the 1st sub-national administrative level reporting cases for the first time ever"; ° In Ethiopia, data for CL include both new and relapse cases.

Monthly distribution of new cases (January-December)

2015	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC
VL	239	215	236	212	158	151	114	108	117	104	174	162
CL	No data											


Number of new CL cases

VL = visceral leishmaniasis; CL = cutaneous leishmaniasis; PKDL= post-kala-azar dermal leishmaniasis; MCL = mucocutaneous leishmaniasis



Incidence rate/10,000 (at the national level) and number of new cases from 1998 to 2015


Visceral leishmaniasis 3000 0.400 Number of new VL cases Number of VL cases 0.350 2500 00000 Incidence rate (/1) 0.300 000) No data 2000 * 5 0.250 rate 1500 0.200 Incidence 0.150 1000 0.100 500 0.050 0.000 0 1998 11998 11999 12999 11999 12999 11999 12999 11999 12999 1




Disease distribution of new VL and CL cases at region level per 10,000 population (2015)

Visceral leishmaniasis

Cutaneous leishmaniasis





www.who.int/leishmaniasis/Map-CL-Ethiopia-2015.png

ww.who.int/leishmaniasis/Map-VL-Ethiopia-2015.png

The boundaries and names shown and the designations used on these maps do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. Map production: WHO/HTM/NTD/IDM

CONTROL AND SURVEILLANCE

Year Leishmaniasis National Control Programme (LNCP) was established:	2006
Type of surveillance:	Integrated
Is there a vector control programme?	No
Type of insecticide used for Indoor residual Spraying (IRS):	None
Year latest national guidelines:	2013
Is leishmaniasis notifiable (mandatory report)?	Yes
Is there a reservoir host control programme?	No
Number of leishmaniasis health facilities:	36

DIAGNOSIS	VL	CLª	PKDL	MCL
Number of people screened actively for:	0	0	N/A	N/A
Number of people screened passively for:	2,141	528	N/A	N/A
Cases diagnosed by RDT* (%, # RDT+/ total VL cases):	77% (1,587/2,063)	N/A	N/A	N/A
Proportion of positive RDT* (%, # RDT+/total RDT):	96% (1,587/1,654)	N/A	N/A	N/A
Cases diagnosed by direct exam (parasitology) (%, # slides + / total cases):	No data	95% (502/528)	N/A	N/A
Proportion of positive slides (%, # slides + / total slides):	No data	95% (502/528)	N/A	N/A
Cases diagnosed clinically (%, # clinical cases/ total cases):	No data	5%	N/A	N/A
Proportion of CL cases with lesions equal to or greater than 4cm:	N/A	5% (26/528)	N/A	N/A
Proportion of CL cases with 4 or more lesions (%, # CL cases/ total CL cases):	N/A	5% (26/528)	N/A	N/A
Percentage of cases with HIV coinfection*:	2% (33/2,063)	N/A	0% (0/11)	N/A

N/A = Not applicable; RDT = rapid diagnostic test; HIV = human immunodeficiency virus ^a Data for CL include both new and relapse cases; * These indicators apply only to new VL cases

TREATMENT AND MEDICINES

Is treatment provided for free in the public sector? Yes

Antileishmanial medicines included in the National Medicine List:

Meglumine antimoniate, Sodium stibogluconate (SSG), Liposomal amphotericin B

	VL	CL
Proportion of cases treated (%, # treated cases/ total cases):	100% (2,063/2,141)	90% (474/528)
Initial cure rate (%, # cases initially cured /total cases):	90% (1,933/2,141)	89% (472/528)
Failure rate4 (%, # patients with treatment failure /total cases):	0.1% (2/2,141)	0% (0/528)
Case fatality rate (%, # patients who died/ total cases):	2% (37/2,141)	0% (0/528)

VL = visceral leishmaniasis; CL = cutaneous leishmaniasis; PKDL= post-kala-azar dermal leishmaniasis; MCL = mucocutaneous leishmaniasis ⁴ Failure in this country is defined as: "The parasitological grade does not decrease after adequate treatment"; ^b Treatment outcome data for both VL and CL include new and relapse cases



© WHO, 2017. All rights reserved